Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker

Zhao, Dan; Wang, Sihua; Yang, Feng; Hua, Chengge; Zhao, Jian; Tang, Xiaodi

doi:10.1016/j.humpath.2010.03.012

Cited by 44 publications

(43 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After title and abstract checking, 36 studies remained for the further evaluating in details, in which 15 articles were excluded for there were no enough data to calculate the survival rate [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27], one article was removed because of duplication [28]. So, a total of 20 publications were fulfilled the eligibility criteria [5][6][7][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45]. Among them, one study was excluded by the poor data quality [45], so 19 publications were included in the final analysis.…”

Section: Literature Searching and Study Characteristicsmentioning

confidence: 99%

“…The details of the procedures of literature screening were shown in Figure 1. Among the 19 studies, 5 studies reported head and neck cancer without site information [7,33,36,39,43], 4 studies focused on oral and oropharyngeal cancer [30,32,40,44], 3 for tongue cancer [6,29,34], 3 for nasopharyngeal cancer [5,35,42], 2 for salivary gland cancer [37,38], 1 for hypopharyngeal cancer [41] and another one for tonsillar cancer [31]. The total number of patients included in the meta-analysis was 2,417, the mean sample size was 127 (ranges from 33 to 396).…”

Section: Literature Searching and Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

WITHDRAWN: A meta-analysis of c-Met expression in head and neck cancer

Li¹,

Sun²,

Sun³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

Section: Literature Searching and Study Characteristicsmentioning

confidence: 99%

Section: Literature Searching and Study Characteristicsmentioning

confidence: 99%

WITHDRAWN: A meta-analysis of c-Met expression in head and neck cancer

Li¹,

Sun²,

Sun³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…12,18 c-Met expression is a prognostic biomarker in HPV-negative HNSCC, with overexpression correlating with reduced disease-free and overall survival. 19,20 Furthermore, c-Met expression has been implicated in resistance to radiation, cisplatin, and cetuximab therapy. 21–23 c-Met overexpression results in enhanced cell motility, angiogenesis, and invasion/metastases, and therefore is an important therapeutic target.…”

Section: Discussionmentioning

confidence: 99%

Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti–Hepatocyte Growth Factor Antibody Ficlatuzumab

Kumar

Kandl

Hamilton

et al. 2015

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

IMPORTANCE Ficlatuzumab can be used to treat head and neck squamous cell carcinoma (HNSCC) by inhibiting c-Met receptor-mediated cell proliferation, migration, and invasion. OBJECTIVE To understand the effect of ficlatuzumab on HNSCC proliferation, migration, and invasion. DESIGN, SETTING, AND PARTICIPANTS The effects of ficlatuzumab on HNSCC proliferation, invasion, and migration were tested. Mitigation of c-Met and downstream signaling was assessed by immunoblotting. The tumor microenvironment has emerged as an important factor in HNSCC tumor progression. The most abundant stromal cells in HNSCC tumor microenvironment are tumor-associated fibroblasts (TAFs). We previously reported that TAFs facilitate HNSCC growth and metastasis. Furthermore, activation of the c-Met tyrosine kinase receptor by TAF-secreted hepatocyte growth factor (HGF) facilitates tumor invasion. Ficlatuzumab is a humanized monoclonal antibody that sequesters HGF, preventing it from binding to and activating c-Met. We hypothesized that targeting the c-Met pathway with ficlatuzumab will mitigate TAF-mediated HNSCC proliferation, migration, and invasion. Representative HNSCC cell lines HN5, UM-SCC-1, and OSC-19 were used in these studies. EXPOSURES FOR OBSERVATIONAL STUDIES The HNSCC cell lines were treated with ficlatuzumab, 0 to 100 µg/mL, for 24 to 72 hours. MAIN OUTCOMES AND MEASURES Ficlatuzumab inhibited HNSCC progression through c-Met and mitogen-activated protein kinase (MAPK) signaling pathway. RESULTS Ficlatuzumab significantly reduced TAF-facilitated HNSCC cell proliferation (HN5, P< .001; UM-SCC-1, P< .001), migration (HN5, P = .002; UM-SCC-1, P = .01; and OSC-19, P = .04), and invasion (HN5, P = .047; UM-SCC-1, P = .03; and OSC-19, P = .04) through a 3-dimensional peptide-based hydrogel (PGmatrix). In addition, ficlatuzumab also inhibited the phosphorylation of c-Met at Tyr1234/1235 and p44/42 MAPK in HNSCC cells exposed to recombinant HGF. CONCLUSIONS AND RELEVANCE We demonstrate that neutralizing TAF-derived HGF with ficlatuzumab effectively mitigates c-Met signaling and decreases HNSCC proliferation, migration, and invasion. Thus, ficlatuzumab effectively mitigates stromal influences on HNSCC progression.

show abstract

“…109 The copy number alteration of proto-oncogene MET (7q31.2) leads to oncogenesis, and is involved in the progression of CRC as a receptor tyrosine kinase. [110][111][112][113] Copy number gain of WNT2 gene (7q31) associates with its overexpression in colorectal adenoma and carcinoma, and its crucial effect on Wnt signaling activation suggests a potential role in CRC initiation. 27,114 Chr8…”

Section: Chr7mentioning

confidence: 99%

Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers

et al. 2015

View full text Add to dashboard Cite

Colorectal cancer (CRC) results from the accumulation of genetic alterations, and somatic copy number alterations (CNAs) are crucial for the development of CRC. Genome-wide survey of CNAs provides opportunities for identifying cancer driver genes in an unbiased manner. The detection of aberrant CNAs may provide novel markers for the early diagnosis and personalized treatment of CRC. A major challenge in array-based profiling of CNAs is to distinguish the alterations that play causative roles from the random alterations that accumulate during colorectal carcinogenesis. In this view, we systematically discuss the frequent CNAs in CRC, focusing on functional genes that have potential diagnostic, prognostic and therapeutic significance.

show abstract

Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker

Cited by 44 publications

References 37 publications

WITHDRAWN: A meta-analysis of c-Met expression in head and neck cancer

WITHDRAWN: A meta-analysis of c-Met expression in head and neck cancer

Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti–Hepatocyte Growth Factor Antibody Ficlatuzumab

Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers

Contact Info

Product

Resources

About